

# Expression Pathology

## FOR IMMEDIATE RELEASE

### Expression Pathology provides Roche its Liquid Tissue<sup>®</sup>-SRM Protein Biomarker Assay Services in Drug Development

**Rockville, MD: January 11, 2011:** Expression Pathology Inc. announced an agreement with Roche (SIX:RO, ROG; OTCQX:RHHBY) wherein Expression Pathology will provide its Liquid Tissue<sup>®</sup>-SRM Technology to accelerate identification of cancer molecular markers for developing more effective treatments.

Under the terms of the agreement, Expression Pathology will support Roche oncology drug development programs with multiplexed quantitative assays of cancer signaling pathway proteins and their activation in FFPE tissues by mass spectrometry.

“This new approach to tissue analysis has the potential to dramatically stream-line and improve biomarker identification in FFPE samples during clinical development,” says Dr. Miro Venturi, Senior Biomarker & Experimental Medicine Leader at Roche. “Longer-term, we may envision Expression Pathology’s Liquid Tissue<sup>®</sup>-SRM platform as becoming a new way of profiling tumors at the molecular level to improve patient stratification and therefore advancing our discovery of personalized medicines.”

“This collaboration with Roche is a key step towards developing valuable clinical assays to improve patient treatment decisions for Roche’s innovative new targeted therapies.” says Casey Eitner, President and CEO of Expression Pathology.

#### **About Expression Pathology Inc.**

Expression Pathology is advancing personalized medicine with assays that measure cancer signaling networks—at the functional protein level—in FFPE tissue to individualize and improve patient treatment decisions. Expression Pathology's patented Liquid Tissue<sup>®</sup>-SRM technology platform makes possible highly multiplexed protein quantitation by powerful mass spectrometry of minute amounts of laser microdissected FFPE tissue.

Expression Pathology offers a broad menu of multiplexed SRM assays for major cancer signaling networks to advance development of targeted therapies and improve patient stratification. The assays include a range of drug target pathway proteins including EGFR, IGF-1R, cMET, Her3, cSRC, MEK, and their phosphorylation states, as well as many others.

For more information contact:

Expression Pathology Inc.  
Peter Tunon, Vice President Sales and Marketing  
9620 Medical Center Drive, Suite 100  
Rockville, MD 20850  
Phone: (301) 977-3654  
E-mail: [p.tunon@expressionpathology.com](mailto:p.tunon@expressionpathology.com)

**Expression Pathology Inc.**

9620 Medical Center Drive • Suite 100 • Rockville, Maryland 20850

phone 301.977.3654 • fax 301.926.9283 • [www.expressionpathology.com](http://www.expressionpathology.com)